期刊文献+

合并症对局限性或局部晚期前列腺癌患者早期生存的影响 被引量:1

Influence of complications on early survival of patients with localized or locally advanced prostate cancer
下载PDF
导出
摘要 目的:应用Charlson合并症指数(CCI),探讨合并症对局限性或局部晚期前列腺癌患者早期生存(3年内)的影响,以期提高对合并症治疗的重视。方法:回顾分析198例局限性或局部晚期前列腺癌患者的临床资料,年龄52-83岁,平均年龄71岁。随访生存情况,分析患者的年龄、合并症情况(CCI)、TNM分期、Gleason评分、病理类型、治疗方式及用药信息等因素对患者早期生存的影响,并比较分析患者生存期之间的差异。结果:在前列腺癌确诊后的第3年,3例(1.51%)患者死于前列腺癌进展发生的远处转移,7例(3.53%)患者死于非癌症相关的其他原因(CCI≥2)。生存分析结果显示,年龄、合并症、用药信息与早期生存相关,CCI≥2的患者中位生存期为26个月。结论:多种因素影响局限性或局部晚期前列腺癌患者的生存与预后,其中合并症是影响患者早期生存的独立因素,积极治疗前列腺癌患者并存的合并症,可能会获得较好的预后。 Objective: To explore the influence of complications on early survival (in 3 years) of patients with localized or locally advanced prostate cancer to enhance public awareness on the therapy of comorbidity. Methods: Clinical data of 198 patients with localized or locally advanced prostate cancer were retrospectively analyzed ,with the patients' age from 52 to 83 and the average being 71. Following-up survival situation was carried out, to study the impact on early survival and compare survival differences, the author made an analysis of various factors, including: age, reasons for treatment, comorbidity, TNM stage, Gleason score, pathological type, therapy , medication information and so on. Results: In the third year after diagnosis, three patients (1.51%) died from prostate cancer metastasis and seven patients (3.53%) died because of other causes which were not related to prostate cancer. The results of single factor analysis showed that age, complication, medication information were related to early survival. Furthermore, the median survival time of patients with Charlson comorbidity index (CCI) ≥2 was 26 months. Conclusion: Many factors can affect early survival of patients with localized or locally advanced prostate cancer.Complications are independent factors affecting early survival patients. Active treatment of complications in prostate cancer patients may achieve good prognosis results.
出处 《天津医科大学学报》 2014年第5期379-382,共4页 Journal of Tianjin Medical University
关键词 前列腺癌 合并症 Charlson合并症指数 早期生存 prostate cancer complications Charlson comorbidity index early survival
  • 相关文献

参考文献19

  • 1王延风,杨敏,彭黎黎,李宁,徐海燕,刘姗,吴艳芳,宋晨鑫,吴晓明,于雷.合并症对老年非小细胞肺癌患者预后及生存的影响[J].中国肿瘤临床与康复,2012,19(3):213-217. 被引量:8
  • 2刘倩,王鹏华,张达,杨蔚,孙茜,褚月颉,李代清.糖尿病足感染截肢(趾)相关危险因素分析[J].天津医药,2013,41(2):110-113. 被引量:16
  • 3叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 4D' amico A V, Braccioforte M H, Moran B J, et al. Causes of death in men with prevalent diabetes and newly diagnosed high- versus fa- vorable-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1329.
  • 5Ketchandji M, Kuo Y F, Shahinian V B, et al. Cause of death in older men after the diagnosis of prostate cancer[J]. J Am Geriatr Soc, 2009, 57(1): 24.
  • 6Hayes J H, Chen M H, Moran B J, et al. Androgen-suppression ther- apy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke[J]. BJU Int, 2010, 106(7): 979.
  • 7Davies B J, Smaldone M C, Sadetsky N A, et al. The impact of obesi- ty on overall and Cancer specific survival in men with prostate can- cer[J]. J Urol, 2009, 182(1): 112.
  • 8Alibhai S M, Leach M, Tomlinson G A, et al. Is there an optimal co- morbidity index for prostate cancer[J]. Cancer, 2008, 112(5): 1043.
  • 9Boulos D L, Groome P A, Brundage M D, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent[J]. Cancer, 2006, 106(8): 1804.
  • 10Singh B, Bhaya M, Stem J, et al. Validation of the charlson comor- bidity index in patients with head and neck cancer: a multi-institu- tional study[J]. Laryngoscope, 1997, 107(11 Pt 1): 1469.

二级参考文献16

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 3Li Y, Burrows NR, Gregg EW, et al. Declining rates of hospitaliza- tion for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: u.s., 1988-2008[J]. Diabetes Care,2012,35(2):273-277.
  • 4Pataky Z, Vischer U. Diabetic foot disease in the elderly[J].Diabetes Metab,2007,33(Suppl 1):$56 - $65.
  • 5Arag6n-S6nchez FJ, Cabrera-Galv6n JJ, Quintana-Marrero Y, et al. Outcomes of surgical treatment of diabetic foot osteomyelitis: a se- ries of 185 patients with histopathological confirmation of bone in- volvement[J]. Diabetologia, 2008,51 ( 11 ): 1962-1970.
  • 6Papanas N, Katsiki N, Papatheodorou K, et al. Peripheral neuropa- thy is associated with increased serum levels of uric acid in type 2 diabetes mellitus[J].Angiology, 2011,62(4):291-295.
  • 7Shankar A, Klein BE, Nieto FJ, et al. Association between serum uric acid level and peripheral arterial disease[J]. Atherosclerosis, 2008, 196(2):749-755.
  • 8Weigelt C, Rose B, Poschen U, et al.Immune mediators in patients with acute diabetic foot syndrome[J]. Diabetes Care, 2009, 32(8): 1491-1496.
  • 9Rattan R, Nayak D. High levels of plasma malondialdehyde, protein carbonyl, and fi brinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: a preliminary com- munication[J]. Int J Low Extrem Wounds, 2008,7(4):198-203.
  • 10O'Hare A, Johansen K, Lower-extremity peripheral arterial disease among patients with end-stage renal disease[J]. J Am Soe Nephrol, 2001, 12(12):2838-2847.

共引文献189

同被引文献6

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部